Dreyling M, Trümper L, von Schilling C, Rummel M, Holtkamp U, Waldmann A, Wehmeyer J, Freund M
Department of Medicine III, Grosshadern, Ludwig Maximilians University, Munich, Germany.
Ann Hematol. 2007 Feb;86(2):81-7. doi: 10.1007/s00277-006-0207-0. Epub 2006 Oct 27.
Radioimmunotherapy (RIT) was approved for the treatment of relapsed or refractory CD20-positive follicular lymphoma (FL), subsequent to rituximab containing primary therapy. However, an increasing number of clinical studies have suggested that RIT may be more efficacious in an earlier phase of the disease. Therefore, a consensus meeting was held in May 2005 to define the optimal setting of RIT in the therapeutic algorithm of patients with advanced stage of FL. RIT is an established therapeutic option in relapsed FL. According to the reviewed data, RIT should be preferably used as consolidation after initial tumor debulking. First-line RIT may be applied in patients not appropriate for chemotherapy induction. Current study concepts evaluate the role of RIT consolidation in combination with antibody maintenance to achieve a potentially curative approach even in patients with advanced stage disease.
放射免疫疗法（RIT）在含利妥昔单抗的初始治疗后，被批准用于治疗复发或难治性CD20阳性滤泡性淋巴瘤（FL）。然而，越来越多的临床研究表明，RIT在疾病的早期阶段可能更有效。因此，在2005年5月召开了一次共识会议，以确定RIT在晚期FL患者治疗方案中的最佳应用时机。RIT是复发FL的一种既定治疗选择。根据综述数据，RIT最好在初始肿瘤减瘤后用作巩固治疗。一线RIT可应用于不适合化疗诱导的患者。目前的研究概念评估了RIT巩固治疗联合抗体维持治疗的作用，以期即使在晚期疾病患者中也能实现潜在的治愈方法。
